作者
Sebastien Hascoët, James R Bentham, Luca Giugno, Pedro Betrián-Blasco, Aleksander Kempny, Ali Houeijeh, Haysam Baho, Shiv-Raj Sharma, Matthew I Jones, Elżbieta Katarzyna Biernacka, Nicolas Combes, Stanimir Georgiev, Hélène Bouvaist, Jose Diogo Martins, Marinos Kantzis, Mark Turner, Stephan Schubert, Zakaria Jalal, Gianfranco Butera, Sophie Malekzadeh-Milani, Estibaliz Valdeolmillos, Clement Karsenty, Ender Ödemiş, Philippe Aldebert, Nikolaus A Haas, Ihab Khatib, Håkan Wåhlander, Gianpiero Gaio, Alberto Mendoza, Sayqa Arif, Biagio Castaldi, Gaute Dohlen, Ronald G Carere, Maria Jesus Del Cerro-Marin, Erwin Kitzmüller, Antony Hermuzi, Mario Carminati, Patrice Guérin, Anja Tengler, Alain Fraisse
发表日期
2024/1/14
期刊
European Heart Journal
卷号
45
期号
3
页码范围
198-210
出版商
Oxford University Press
简介
Background and Aims
Transcatheter pulmonary valve implantation (TPVI) is indicated to treat right-ventricular outflow tract (RVOT) dysfunction related to congenital heart disease (CHD). Outcomes of TPVI with the SAPIEN 3 valve that are insufficiently documented were investigated in the EUROPULMS3 registry of SAPIEN 3-TPVI.
Methods
Patient-related, procedural, and follow-up outcome data were retrospectively assessed in this observational cohort from 35 centres in 15 countries.
Results
Data for 840 consecutive patients treated in 2014–2021 at a median age of 29.2 (19.0–41.6) years were obtained. The most common diagnosis was conotruncal defect (70.5%), with a native or patched RVOT in 50.7% of all patients. Valve sizes were 20, 23, 26, and 29 mm in 0.4%, 25.5%, 32.1%, and 42.0% of patients, respectively. Valve implantation was successful …
学术搜索中的文章
S Hascoët, JR Bentham, L Giugno, P Betrián-Blasco… - European Heart Journal, 2024